English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12340/13424 (92%)
Visitors : 1967468      Online Users : 98
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11407


    Title: Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication
    Authors: Yeo, YH;Hsu, CC;Lee, CC;Ho, HJ;Lin, JT;Wu, MS;Liou, JM;Wu, CY;Taiwan Gastrointestinal Disease and Helicobacter Consortium
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND AND AIM: The eradication rate of Helicobacter pylori has been declining over the past decades. A rescue plan is needed for increasing populations with treatment failure. However, the optimum second-line eradication regimen remains inconclusive. We conducted a network meta-analysis to assess the comparative effectiveness of second-line Helicobacter pylori (H. pylori) eradication therapies and determine the optimum regimen. METHODS: We searched electronic databases from January 2005 to Feb 2018 for randomized controlled trials assessing the effectiveness of second-line regimens in patients with persistent H. pylori infection after first-line treatment. Bayesian network meta-analysis (NMA) was performed to combine the direct and indirect evidence and to investigate the rank order of second-line therapies. We also appraised the quality of evidence using GRADE guidance. RESULTS: Twenty-six trials with 3,628 participants who received second-line eradication therapy were identified. All regimens showed pooled eradication rates <90%. Compared with 7-day triple therapy, quinolone-based (odds ratio [OR] 4.29, 95% credible interval [CrI] 1.67-12.12, SUCRA 0.95) and non-quinolone-based bismuth-containing quadruple therapies for 10 days or more (OR 2.25, 95% CrI 1.10-4.62, SUCRA 0.78) and sequential therapy (OR 2.91, 95% CrI 1.16-7.65, SUCRA 0.66) showed significantly higher effectiveness. Overall, regimens with longer duration demonstrated higher eradication rates but higher rates of adverse events. More adverse events were reported in those patients treated with concomitant therapy. CONCLUSIONS: Quinolone-based bismuth-containing quadruple therapies for 10 days or more are the optimum regimens for H. pylori eradication.
    Date: 2019-01
    Relation: Journal of Gastroenterology and Hepatology. 2019 Jan;34(1):59-67.
    Link to: http://dx.doi.org/10.1111/jgh.14462
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0815-9319&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000455896500012
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85054826093
    Appears in Collections:[林肇堂] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB30169908.pdf1228KbAdobe PDF124View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback